Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining, causing chronic gastritis, peptic ulcers, and increasing the risk of gastric lymphoma and carcinoma.
It is one of the most common chronic bacterial infections worldwide, affecting up to 50% of the global population, with higher prevalence in developing countries.
H. pylori is typically acquired in early childhood and can persist without treatment. The bacterium's ability to survive in the acidic environment of the stomach is attributed to various virulence factors.
Its high mutation and recombination rates lead to extensive strain diversity.
While many infected individuals remain asymptomatic, H. pylori can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia when gastritis or peptic ulcer disease develops.
Diagnosis involves non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy. Treatment generally includes a combination of proton pump inhibitors and antibiotics.
The dupA (duodenal ulcer promoting gene A) is a virulence factor of H. pylori that is associated with an increased risk of duodenal ulcers in certain geographical regions. It is located in the plasticity region of the H. pylori genome.
DupA has been linked to increased inflammatory responses, such as elevated levels of interleukin-8 (IL-8) and inflammatory cell infiltration in the gastric mucosa of H. pylori-infected individuals.
However, the role of dupA in the pathogenesis of H. pylori-related diseases remains controversial, with conflicting findings across different populations and geographical regions.
Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium that infects the stomach lining and is a common cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma.
It affects up to 50% of the global population, with higher prevalence in developing countries. It is one of the most common chronic bacterial infections worldwide.
H. pylori is typically acquired in early childhood and persists without treatment.
It is able to survive in the harsh acidic environment of the stomach due to its unique features like flagella for motility and urease enzyme production.
Its genome exhibits high mutation and recombination rates, leading to extensive strain diversity. [9., 12.]
While many infected individuals remain asymptomatic, the bacteria can cause symptoms such as abdominal pain, nausea, vomiting, and dyspepsia once gastritis or peptic ulcer disease develops. H. pylori infection causes chronic gastritis in all cases and increases the risk of peptic ulcers by 2-6 fold and gastric cancer by 2-6 fold compared to uninfected individuals. [5., 9.]
Transmission occurs through fecal-oral, oral-oral, and gastric-oral routes, with lower socioeconomic status being a significant risk factor.
Diagnosis involves both non-invasive methods like urea breath tests and stool antigen tests, and invasive methods such as endoscopic biopsy.
Treatment often includes a combination of proton pump inhibitors and antibiotics. Antibiotic combination therapies like clarithromycin triple therapy or bismuth quadruple therapy may be used. [5.]
Early identification and treatment of H. pylori infections are crucial to prevent serious gastrointestinal diseases and potential malignancies. Collaboration among healthcare professionals is essential for effective management and improved patient outcomes.
H. pylori virulence factors refer to the various bacterial components and mechanisms that enable the pathogen Helicobacter pylori to successfully colonize the human stomach, evade the host's immune defenses, and cause associated diseases and complications.
The H. pylori Virulence Factor dupA is a gene located within the plasticity regions of the Helicobacter pylori genome. Its role in disease progression and pathogenicity has been an area of active research due to conflicting reports from different geographical regions.
The dupA (duodenal ulcer promoting) gene, located in the plasticity region of the H. pylori genome, was identified in 2005.
It has been associated with an increased risk of DU and a decreased risk of gastric cancer (GC) in certain geographic regions. Research on dupA has shown varied results, making it a subject of ongoing investigation to understand its role in disease progression. [1.]
In East Asia and South America, dupA is associated with a higher risk of DU and a lower risk of GC. However, studies from Belgium, South Africa, China, North America, and Brazil found no significant link between dupA and DU.
The association between dupA and disease outcomes varies significantly by region. This discrepancy may be due to differences in study populations, genetic variations within the H. pylori strains, and methodologies used for detecting dupA.
Studies have identified two alleles, dupA1 (intact) and dupA2 (truncated). Only the intact dupA1 is associated with increased interleukin (IL)-12 and IL-8 production, suggesting a role in inflammation and disease progression. [1.]
DupA functions according to the type IV secretion system (T4SS) which is also seen in other bacteria, indicating its potential role in protein and DNA transfer. Its participation in the T4SS system contributes to its bacterial colonization and pathogenicity.
Despite the extensive research, the role of dupA in H. pylori pathogenicity remains inconclusive. Its association with DU and GC varies by region, and further studies are needed to clarify its function and potential as a biomarker for gastric diseases.
Understanding the precise role of dupA, especially in combination with other virulence factors, will be crucial for developing targeted therapies and diagnostic tools for H. pylori infections.
Laboratory testing for H. pylori virulence factors typically involves a stool sample, which is tested via polymerase chain reaction (PCR) for H. pylori virulence factors.
The stool sample may be collected at home. While special preparation is not typically required for this assessment, other test components may require special preparation such as avoidance of certain foods, supplements or medications.
Click here to discover a laboratory test that assesses for H. pylori and virulence factors.
H. pylori infections can cause serious conditions including peptic ulcer disease and gastric cancer, and the presence of virulence factors such as the dupA virulence factor may increase the risk of developing serious disease.
Optimal levels of H. pylori virulence factor dupA are undetectable.
A positive test result indicates the presence of H. pylori and the virulence factor dupA, which requires prompt treatment.
Typical first-line eradication therapies may include medications such as clarithromycin, bismuth, amoxicillin, metronidazole, or tetracycline in combination, along with a PPI.
The presence of dupA-positive strains may indicate the need for more intensive therapies, including anti-inflammatory and demulcent compounds, as some research has linked it with ulcer promotion. [1.]
With the increase in antibiotic resistance demonstrated by H. pylori, especially in the setting of virulence factor-positive strains, scientists are exploring alternative methods of treating H. pylori including botanical therapies. Some botanical compounds that have shown promise in treating H. pylori include: [6.]
In addition to the dupA virulence factor, several other biomarkers have been identified and studied in the context of H. pylori infection and associated gastric diseases.
The cytotoxin-associated gene A (CagA) is a major virulence factor of H. pylori that has been extensively studied for its role in gastric cancer development.
The presence of CagA has been strongly associated with an increased risk of gastric cancer.
In Western countries, infection with BabA-producing strains is associated with an increased risk of peptic ulcer disease.
A recent study indicated that BabA-positive H. pylori strains have a higher adherence to epithelial cells and are often found in pediatric ulcerogenic H. pylori strains.
BabA-positive H. pylori strains can be classified as "specialists," which bind only blood group O-specific glycans, or "generalists," which bind glycans of blood groups O, A, and B.
The ability of these strains to bind specifically to blood group O glycans explains why individuals with blood group O are at a higher risk for developing duodenal ulcers.
The vacuolating cytotoxin A (VacA) is another important virulence factor of H. pylori that contributes to the pathogenesis of peptic ulcers. VacA induces the formation of vacuoles in gastric epithelial cells, leading to cellular damage and disruption of the gastric mucosal barrier.
The presence of the vacA gene and its specific allelic variations have been linked to an increased risk of peptic ulcer disease and gastric inflammation.
In addition to bacterial virulence factors, serological biomarkers such as anti-H. pylori antibodies can also be used for the diagnosis and monitoring of H. pylori infection.
These antibodies are produced by the host's immune system in response to the bacterial antigens and can be detected in serum or plasma samples.
Helicobacter pylori (H. pylori) is a type of bacteria that infects the stomach lining and is a common cause of peptic ulcers, chronic gastritis, and is associated with an increased risk of stomach cancer.
A virulence factor is a molecule produced by a pathogen (such as bacteria, viruses, fungi, and protozoa) that enables it to colonize the host, evade the immune system, and cause disease.
dupA (duodenal ulcer-promoting gene A) is a virulence factor found in certain strains of H. pylori. It is associated with an increased risk of duodenal ulcers and has been linked to higher inflammatory responses in the host.
The dupA (duodenal ulcer promoting) gene, located in the plasticity region of the H. pylori genome, was first identified in 2005. It has been associated with an increased risk of duodenal ulcer and a decreased risk of gastric cancer (GC) in certain geographic regions.
Research on dupA has shown varied results, making it a subject of ongoing investigation to understand its role in disease progression.
dupA can be detected through molecular testing methods such as PCR (polymerase chain reaction) and sequencing, which identify the presence of the dupA gene in H. pylori samples.
Research has demonstrated varying responses to infections with H. pylori strains that express the dupA virulence factor.
These strains may be more likely to cause duodenal ulcers and may lead to higher levels of inflammation and tissue damage.
The treatment for an H. pylori infection with the dupA virulence factor is similar to treatment for other H. pylori infections, typically involving a combination of antibiotics and acid-suppressing medications.
However, awareness of the presence of dupA can help healthcare providers anticipate a potentially more aggressive infection and tailor treatment accordingly.
While antibiotics are necessary to eradicate H. pylori, lifestyle changes can help manage symptoms and reduce the risk of complications. These include:
To reduce the risk of H. pylori infection, practice good hygiene, such as washing hands thoroughly with soap and water, eating food that has been properly prepared and cooked, and drinking water from a safe, clean source.
For more information about H. pylori and the dupA virulence factor, consider consulting:
Click here to compare testing options and order tests for H. pylori.
[1.] Alam J, Sarkar A, Bipul Chandra Karmakar, Ganguly M, Paul S, Mukhopadhyay AK. Novel virulence factor dupA of Helicobacter pylori as an important risk determinant for disease manifestation: An overview. World journal of gastroenterology. 2020;26(32):4739-4752. doi:https://doi.org/10.3748/wjg.v26.i32.4739
[2.] Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. PMID: 31752394; PMCID: PMC6891454.
[3.] Chakrani, Z., Robinson, K. & Taye, B. Association Between ABO Blood Groups and Helicobacter pylori Infection: A Meta-Analysis. Sci Rep 8, 17604 (2018). https://doi.org/10.1038/s41598-018-36006-x
[4.] Chang, WL., Yeh, YC. & Sheu, BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci 25, 68 (2018). https://doi.org/10.1186/s12929-018-0466-9
[5.] Connor B. Helicobacter Pylori | CDC Yellow Book 2024. wwwnc.cdc.gov. Published 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/helicobacter-pylori
[6.] Deng R, Chen X, Zhao S, Zhang Q, Shi Y. The effects and mechanisms of natural products on Helicobacter pylori eradication. Frontiers in cellular and infection microbiology. 2024;14. doi:https://doi.org/10.3389/fcimb.2024.1360852
[7.] Donelli LC Gianfranco. Virulence Factors of Helicobacter pylori. Microbial Ecology in Health and Disease. 2000;12(2):259-262. doi:https://doi.org/10.1080/089106000750060512
[8.] Doohan D, Rezkitha YAA, Waskito LA, Yamaoka Y, Miftahussurur M. Helicobacter pylori BabA–SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins. 2021;13(7):485. doi:https://doi.org/10.3390/toxins13070485
[9.] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8
[10.] Parikh NS, Ahlawat R. Helicobacter Pylori. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534233/
[11.] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis. 2013 Jul;14(7):341-9. doi: 10.1111/1751-2980.12054. PMID: 23452293; PMCID: PMC3721066.
[12.] Thorell, K., Muñoz-Ramírez, Z.Y., Wang, D. et al. The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun 14, 8184 (2023). https://doi.org/10.1038/s41467-023-43562-y